Revolution Medicines’ Allure: How Mooted $30 Billion Valuation Puts Focus on Biotech: BI Replay

On Demand

Duration: 38 Minutes

Original Date: January 08, 2026

First name

Last name

Business email

Business phone

Company

Job role

Industry

City

Country or Region

State or Province Optional

Yes, I would like to be contacted by a representative to learn more about Bloomberg's solutions and services.

What are you interested in learning more about?

By submitting this information, I agree to the privacy policy and to learn more about products and services from Bloomberg.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Join Sam Fazeli and Javier Manso Polo to discuss Revolution Medicines’ pipeline, the AbbVie and Merck takeover interest, what the reported valuations suggest, and how the company fits in the KRAS-mutant cancer market.

Revolution Medicines’ Allure: How Mooted $30 Billion Valuation Puts Focus on Biotech: BI Replay

Access a broad range of analysis, research, insight and actionable ideas with Bloomberg webinars.